Last reviewed · How we verify

TAK-931 Tablet

Millennium Pharmaceuticals, Inc. · Phase 2 active Small molecule

TAK-931 Tablet is a Small molecule drug developed by Millennium Pharmaceuticals, Inc.. It is currently in Phase 2 development.

TAK-931 is an investigational drug developed by Millennium Pharmaceuticals, Inc. It has completed a Phase 1 study assessing its bioavailability, food effects, and pharmacokinetics in patients with advanced solid tumors. No FDA label is available, and further clinical development is needed.

At a glance

Generic nameTAK-931 Tablet
SponsorMillennium Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAK-931 Tablet

What is TAK-931 Tablet?

TAK-931 Tablet is a Small molecule drug developed by Millennium Pharmaceuticals, Inc..

Who makes TAK-931 Tablet?

TAK-931 Tablet is developed by Millennium Pharmaceuticals, Inc. (see full Millennium Pharmaceuticals, Inc. pipeline at /company/millennium-pharmaceuticals-inc).

What development phase is TAK-931 Tablet in?

TAK-931 Tablet is in Phase 2.

Related